MET and cancer: MET, a transmembrane tyrosine kinase receptor for hepatocyte growth factor (HGF), has been observed to contribute to cancer metastasis, resistance to chemotherapeutic agents, and dismal outcomes of patients with solid cancers including HCC [7–10].